ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL2547 |
|
83280-65-3 |
Napabucasin(BBI608) 98+% |
C14H8O4 | |
CL2531 |
|
1640292-55-2 |
Oclacitinib Maleate (PF-03394197 Maleate) 98+% |
C19H27N5O6S | |
CLA1355 |
|
1447814-75-6 |
Brontictuzumab (Anti-NOTCH1) 95+% |
— | |
CLA1337 |
|
1345009-45-1 |
Vantictumab (Anti-FZD) 95+% |
— | |
CLA1334 |
|
1359940-55-8 |
Tarextumab (Anti-NOTCH3) 95+% |
— | |
CLA1299 |
|
1243262-17-0 |
Demcizumab (Anti-DLL4) 95+% |
— | |
HL1389 |
|
88495-63-0 |
Artesunate 98+% |
C19H28O8 | |
CL2213 |
|
686770-61-6 |
N -(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2- d ]pyrimidin-2-yl)thio]-acetamide 98+% |
C22H18N4O2S3 | |
CL1172 |
|
331752-47-7 |
Y27632 HCl hydrate,(R)-(+)-trans-4-(1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide Dihydrochloride Monohydrate/Y-27632 Dihydrochloride Monohydrate 98+% |
C14H25Cl2N3O2 | |
CL1037 |
|
879085-55-9 |
Vismodegib (GDC-0449) 98+% |
C19H14Cl2N2O3S | |
CL1011 |
|
780757-88-2 |
ICG-001(ICG 001); (S,S)-ICG 001 98+% |
C33H32N4O4 | |
CL1120 |
|
477600-75-2 |
Tofacitinib (Tasocitinib; CP-690550) 98+% |
C16H20N6O | |
CL2178 |
|
284028-89-3 |
XAV-939 98+% |
C14H11F3N2OS | |
CL2177 |
|
857064-38-1 |
WP1066 98+% |
C17H14BrN3O | |
HL1009 |
|
4449-51-8 |
Cyclopamine (11-deoxojervine) 98+% |
C27H41NO2 | |
CL1006 |
|
252917-06-9 |
Laduviglusib (CHIR-99021; CT99021) 99+% |
C22H18Cl2N8 | |
CL1003 |
|
129830-38-2 |
Y-27632 Dihydrochloride; Y-27632 2HCl 98+% |
C14H21N3O.2HCl | |